CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $120.00

CRISPR Therapeutics (NASDAQ:CRSP) had its price target raised by Truist Financial from $100.00 to $120.00 in a research note released on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other analysts have also issued reports on CRSP. HC Wainwright assumed coverage on CRISPR Therapeutics in a report on Monday, February 3rd. They set a “buy” rating and a $65.00 target price on the stock. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Barclays upped their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a report on Wednesday. Chardan Capital reissued a “buy” rating and set a $94.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Finally, Royal Bank of Canada lowered their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $74.50.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $49.72 on Wednesday. The firm has a market cap of $4.26 billion, a price-to-earnings ratio of -17.57 and a beta of 1.67. The stock’s 50-day moving average is $41.89 and its 200-day moving average is $46.17. CRISPR Therapeutics has a one year low of $36.52 and a one year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. On average, equities analysts expect that CRISPR Therapeutics will post -5.08 EPS for the current year.

Insider Activity

In other news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares of the company’s stock, valued at approximately $10,002,854. This represents a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors have recently made changes to their positions in the stock. Highline Wealth Partners LLC bought a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $39,000. Western Pacific Wealth Management LP boosted its stake in shares of CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after buying an additional 500 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of CRISPR Therapeutics in the third quarter valued at approximately $40,000. Darwin Wealth Management LLC bought a new stake in shares of CRISPR Therapeutics in the third quarter valued at approximately $43,000. Finally, Eastern Bank bought a new stake in shares of CRISPR Therapeutics in the third quarter valued at approximately $70,000. 69.20% of the stock is currently owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.